Your molecule.
Latin America.
One partner.
We are the strategic layer between global pharma manufacturers and the Latin American pharmaceutical market — with active operations in Mexico, Central America & the Caribbean. One U.S.-based entity managing compliance, contracts, regulatory affairs, institutional tenders, and distribution across the region.
Mercado Farmacéutico Latinoamericano
Entering Latin America without the right infrastructure costs more than the market is worth.
Regulatory Complexity
6 different regulatory frameworks. RTCA harmonization covers some — but each country has its own timelines, fees, and local requirements.
Institutional Access Gap
CSS, CCSS, IGSS, IHSS, ISSS, SeNaSa represent 60%+ of the regional pharma market. You can’t reach them without local institutional relationships.
Channel Risk
Generic distributor networks don’t specialize. Most manufacturers who enter Latin America without the right partner face years of underperformance and channel failures before finding the right path.
Multi-country Coordination Cost
Managing 6 separate country relationships, contracts, and distributors multiplies administrative cost and compliance risk with no economies of scale.
There is a better way to access Latin America. Not by building infrastructure country by country — but by partnering with the team that has already built it across Mexico, Central America and the Caribbean.
One U.S. entity. Latin America covered
You work with one team. One contract. One counterparty under U.S. law. We handle everything that follows.
Fabricantes Globales
LMG Bio Lifesciences LLC (Miami, FL)
The interface layer. This is where manufacturers engage. We handle: international contracts under U.S. law · compliance & regulatory strategy · licensing agreements · supply chain coordination · market intelligence (IQVIA) · institutional tender strategy. You sign one contract. We manage the rest — across Mexico, Central America, and the Caribbean, with a clear roadmap to the rest of Latin America.
Lanco Medical Group · Regional Operations
The execution layer. 30+ years building the infrastructure that makes Latin America work. Operating across Mexico, Panama, Costa Rica, Guatemala, Honduras, El Salvador & Dominican Republic: RTCA regulatory filings · institutional tender management · qualified distribution network · medical sales force · key account management in public & private sector.
The Market · $80B+ Latin American Regional Opportunity
CSS (Panama) · CCSS (Costa Rica) · IGSS (Guatemala) · IHSS (Honduras) · ISSS (El Salvador) · SeNaSa (Dominican Republic). Over 144 million units consumed in the region in 2025. Public and private channels. Biosimilars, specialty molecules, generics.
Built for pharma.
Proven across Latin America
Cinco capacidades. Un socio integrado.
We don’t enter markets blind. IQVIA data gives us real prescription data, market share, and pricing benchmarks for every therapeutic area across Latin America — from Mexico to the Caribbean. Before we propose a strategy, we show you the numbers.
Our team manages CTD dossiers for generics, biosimilars, and biologics across the RTCA framework. 83–100 point checklists per country. Active registrations maintained. We’ve never lost a file to a procedural error.
Direct relationships — not intermediary contacts — with CSS, CCSS, IGSS, IHSS, ISSS, and SeNaSa. We’ve won tenders, not just participated in them. The largest contract in CCSS history in our therapeutic area was ours.
Seven-plus active markets across Latin America. Zero generic intermediaries. Our distribution partners are vetted, specialized in institutional pharma, and managed with key account discipline. They sell; they don’t just warehouse.
LMG Bio Lifesciences LLC is incorporated in the United States. Contracts are under U.S. law. Your legal team can validate the structure in hours. We are the counterpart that global manufacturers can trust before they trust the region.
Trusted by global manufacturers. Proven across Latin America
Our current portfolio partners include world-class manufacturers who have chosen LMG Bio as their strategic access partner for Latin America:
Zydus Lifesciences · Macleods Pharmaceuticals · Samsung Bioepis · LG Chem · Daewoong Pharmaceutical · Dr. Reddy’s Laboratories
Years building pharma infrastructure across Latin America
Active markets across Latin America — Mexico, Central America & the Caribbean
Units consumed through our network in 2025
U.S.-based entity. One contract. Total regional coverage.
We're not building a transaction
We're building the infrastructure of access across Latin America
Latin America is the most dynamic pharmaceutical market in the Western Hemisphere — over $80B and growing. Mexico alone represents the largest Spanish-speaking pharma market in the world. Central America and the Caribbean add seven countries with growing institutional demand and underserved therapeutic areas. The opportunity is massive. The infrastructure to capture it has been fragmented, complex, and hard to navigate for global manufacturers. Until now.
We’re changing that. LMG Bio is building the platform that will define how global pharma accesses Latin America for the next decade. Our partners don’t just get distribution — they get a stake in the infrastructure.
Our partners don't just gain distribution. They gain a stake in the infrastructure
Strategic hub. Miami, FL. International contracts, compliance, licensing, market intelligence.
Regional operations. 6 countries. 30+ years. Tenders, RTCA, distribution, sales force.
U.S. institutional access. Government procurement (GSA, VA, DOD). For partners with U.S. market ambition.
Your molecule is already losing market share in Latin America. Let's talk
In 20 minutes, we can tell you:
▸ The revenue potential of your molecule across Latin America (IQVIA data, by country — prioritizing Mexico, Central America & the Caribbean)
▸ Whether a competitor is already in the market — and how we can respond
▸ The fastest regulatory path to your first Latin American market
▸ What a partnership with LMG Bio actually looks like for your product
No generic proposals. No sales pitch. Just a focused conversation with data
STRATEGIC ACCESS TO THE LATIN AMERICAN PHARMACEUTICAL MARKET.
A US-based entity. Complete regional coverage